Dr. Besse on the Safety of Selpercatinib in Advanced RET+ Thyroid Cancer, NSCLC
April 10th 2021Benjamin Besse, MD, discusses the results of an ad-hoc safety analysis of the phase 1/2 LIBRETTO-001 trial, which examined the use of selpercatinib in patients with RET-altered advanced medullary thyroid cancer and non–small cell lung cancer.
Read More